Abstract Library

#2116 Ghrelin O-Acyltransferase (GOAT) Enzyme and Ghrelin Receptor GHSR1a as Putative Prognosis Markers and Therapeutic Targets in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Specific components of ghrelin-system are associated with tumor development/ progression. We have previously described the presence of this system in neuroendocrine tumors (NETs) but clinical-molecular correlations have not been elucidated yet.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Herrera-Martinez A

Authors: Herrera-Martínez A, Gahete M, Sánchez-Sánchez R, Ortega Salas R, Serrano R,

Keywords: GEP-NET, ghrelin system, GOAT, GHSR1a, prognosis, invasion,

#1566 Splicing Dysregulation Impacts on Neuroendocrine Tumors: Evidence from Altered Spliceosoma Components and Somatostatin and Ghrelin Systems.

Introduction: Splicing is an emerging cancer hallmark influencing multiple tumor cell (dys)functions. We have shown that aberrantly spliced variants of somatostatin receptor subtype 5 (sst5TMD4) and of the pleiotropic neuropeptide ghrelin (in1ghrelin) are linked to poor prognosis in gastroenteropancreatic neuroendocrine tumors (GEPNETs) and may enhance their aggressiveness features.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Castaño J

Authors: Castaño J, Pedraza-Arevalo S, Herrea-Martinez A, Del Río-Moreno M, Sánchez-Sánchez R,

Keywords: Splicing,

#521 Cachexia in Pancreatic Neuroendocrine Tumors: A Comparison with Pancreatic Adenocarcinoma

Introduction: Patients with pancreatic cancer (pCA) have a high propensity for cachexia even in the absence of metastases. On the other hand, patients with pancreatic neuroendocrine tumors (pNET) often maintain their weight and muscle mass for a long period of time even with liver metastases.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Mallath M, Shrikhande S, Patil P, Mehta S, Goel M,

Keywords: cachexia, ghrelin, cancer, nutrition,

#140 Serotonin expression in gastric neuroendocrine tumors and in foci of endocrine cell hyperplasia

Introduction: The most abundant neuroendocrine (NE) cell population of the human oxyntic mucosa is the enterochromaffin-like (ECL) cells, followed by ghrelin, somatostatin and serotonin cells, respectively. All types of ECL cell carcinoids (ECL-CCs) contain serotonin cells but in a varying frequency. Hitherto, only foci of ECL and ghrelin cell hyperplasia have been described in the peritumorous mucosa of types I and II ECL-CCs. It is established that hypergastrinaemia can cause ECL cell hyperplasia but it does not affect serotonin cells. The vesicular monoamine transporter 2 (VMAT 2) is used as an immunohistochemical marker for ECL cells.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Tsolakis A

Authors: Tsolakis A, Falkmer S, Grimelius L,

Keywords: enterochromaffin-cell carcinoids, immunohistochemistry, serotonin cell hyperplasia, VMAT 2,

#46 Neuroendocrine markers are expressed in human mammary glands

Introduction: Regulatory peptides have previously been detected in epithelial cells of human mammary glands. As these peptides are produced by scattered neuroendocrine cells in the epithelium of other tissues the aim of this study was to investigate whether the mammary glands express molecular markers for neuroendocrine cells.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Grönberg M, Amini R, Stridsberg M, Janson E, Saras J,

Keywords: Breast; Chromogranin; Ghrelin; Obestatin; Secretogranin; Vesicular monoamine transporter,